ACARBOSE (acarbose) by Hikma is alpha glucosidase inhibitors [moa]. Approved for alpha-glucosidase inhibitor [epc]. First approved in 2008.
Drug data last refreshed 20h ago
alpha Glucosidase Inhibitors
alpha-Glucosidase Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Learn More About How Acarbose and Metformin Work When Taken Together and How Safe They Are in Indian Patients Who Were Recently Diagnosed With Type 2 Diabetes (T2D)
Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose
Bioequivalence Study for Acarbose/Metformin FDC
Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive
A Study for Sufficient Acarbose Decreased Glucose Excursion in Type 2 Diabetic Patients
Worked on ACARBOSE at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.